Parmax Pharma (BOM:540359) Total Liabilities: ₹342.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540359 Parmax Pharma Ltd BOM:540359
39 GF Score
Price ₹102.92
GF Value ₹25.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Parmax Pharma Total Liabilities?

Parmax Pharma BOM:540359 +1.99% 39 Total Liabilities is ₹342.0 Mil as of Mar. 2026. GuruFocus rates BOM:540359 with a GF Score™ of 39/100 and a GF Value™ of ₹25.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Parmax Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was ₹342.0 Mil.

Parmax Pharma's quarterly Total Liabilities declined from Sep. 2025 (₹224.62 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹342.01 Mil).

Parmax Pharma's annual Total Liabilities increased from Mar. 2024 (₹152.25 Mil) to Mar. 2025 (₹207.41 Mil) and increased from Mar. 2025 (₹207.41 Mil) to Mar. 2026 (₹342.01 Mil).

Parmax Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Parmax Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma Total Liabilities Chart

Parmax Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.15 117.57 152.25 207.41 342.01

Parmax Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.41 0.00 224.62 0.00 342.01
BOM:540359
39GF Score
Parmax Pharma Ltd BOM:540359
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parmax Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Parmax Pharma's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=226.828+(115.182+-1.4210854715202E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=342.0

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=280.533--61.478
=342.0

Parmax Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=226.828+(115.182+-1.4210854715202E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=342.0

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=280.533--61.478
=342.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹342.0 Mil mean?
Parmax Pharma (BOM:540359) has a Total Liabilities of ₹342.0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Parmax Pharma and its competitors.
Is Parmax Pharma's Total Liabilities too high?
Parmax Pharma's current Total Liabilities is ₹342.0 Mil. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Total Liabilities compare to ZTS and UTHR?
Parmax Pharma's Total Liabilities of ₹342.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Parmax Pharma and its competitors. Parmax Pharma's current Total Liabilities is ₹342.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.56, compared to a current price of ₹102.92 — trading 302.7% above its estimated fair value. The current Total Liabilities is ₹342.0 Mil. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Total Liabilities is ₹342.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parmax Pharma (BOM:540359) Overvalued in 2026?

Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued. The current stock price of ₹102.92 is trading 302.7% above its estimated GF Value™ of ₹25.56. GuruFocus considers Parmax Pharma to be Significantly Overvalued.

Key valuation signals for BOM:540359:

  • Total Liabilities: ₹342.0 Mil
  • GF Value™: ₹25.56 vs. price of ₹102.92 (302.7% above fair value)
  • GF Score™: 39/100 with 8 warning signs

No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Parmax Pharma Business Description

Address Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its Core Segments: Anti-infectives, Analgesics & anti-inflammatory, Cardiovascular APIs, General oral formulations (tablets, capsules) Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
39GF Score

Get the complete analysis for BOM:540359

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹102.92
Price
₹25.56
GF Value